Facial Skin With Conspicuous Enlarged Pores Closely Related to Severity of Facial Acneiform Rash and Therapeutic Effects of EGFR Inhibitors in RAS Wild-Type Metastatic Colorectal Cancer: Ancillary Analysis of FAEISS Study (NCCH1512).
Shusuke Yoshikawa, Katsuko Kikuchi, Keiko Nozawa, Yasuko Nakai, Haruhiko Fukuda, Taro Shibata, Ryunosuke Machida, Tetsuya Hamaguchi, Atsuo Takashima, Sumiko Takatsuka, Tomohiro Nishina, Akihito Kawazoe, Takahiro Tsushima, Masanobu Takahashi, Akiko Hasegawa, Toshiki Masuishi, Naoya Yamazaki, Yoshio Kiyohara
J Dermatol 52(8) 1227-1231
摘要
摘要
Prophylactic treatment with oral minocycline or doxycycline, moisturizers, and sunscreens has been reported to be beneficial for acneiform rash (AfR) caused by epidermal growth factor receptor (EGFR) inhibitors. It is desirable to predict which patients may develop severe AfR and provide prophylactic treatment. This study aimed to evaluate the association between the worst grade of facial AfR (FAfR) after initiating therapy with EGFR inhibitors and the characteristic skin type in patients with RAS wild-type metastatic colorectal cancer enrolled in the FAEISS study (a phase III, open-label, randomized trial evaluating topical corticosteroids for Facial Acneiform dermatitis by EGFR Inhibitors: Stepwise rank down from potent corticosteroids). Using pretreatment photographs of the face, characteristic skin types, including enlarged pores, oiliness (greasiness), and skin color/redness, were graded on a scale of 1-3. Grade 2 or higher FAfR developed in 9.1%, 27.0%, and 45.8% of patients with enlarged pore scores of 1, 2, and 3, respectively. Patients with enlarged pores tended to have more severe FAfR (p = 0.0216). Moreover, the disease control rate (complete remission/partial remission/stable disease) of the primary disease was seen in 59.1%, 70.6%, and 87.0% of patients with an enlarged pore score of 1, 2, and 3, respectively, showing a statistically significant trend (p = 0.038). This study suggests that a facial skin type with a high number of enlarged pores may be a marker for predicting AfR risk due to anti-EGFR antibody therapy and better therapeutic effects for RAS wild-type metastatic colorectal cancer.
KM 提取结果
0 个 Figure · 0 个 KM 面板
其他 Figure(1,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。